screening for H. pylori, Hansen et al. 2 reported that H. pylori eradication resulted in a decreased ulcer incidence. Such effect of decrease of prevalence of H. pylori and, therefore, decrease of incidence of peptic ulcer between dialysis and non-dialysis groups seems discrepant. 1,2 We believe that factors aside from H. pylori play an important role in the occurrence of peptic ulcer in dialysis patients. In our 2-year follow-up study after H. pylori eradication, we found that peptic ulcer recurred more in dialysis patients than in nondialysis patients, with intention to treat analysis (8/32, 25 vs 2/64, 3.1%, P ¼ 0.001, OR: 10.000, 95% CI: 1.979-50.540) or per protocol analysis (8/29, 27.5 vs 2/64, 3.1%, P ¼ 0.001, OR: 11.429, 95% CI: 2. 245-58.168). 3 In addition, dialysis patients often need aspirin for cardiovascular disease or NSAIDs for arthralgia. 3,4 In Sugimoto et al.'s study, the condition of aspirin/NSAIDs usage is lacking; therefore, the conclusion may be misleading when evaluating the incidence of peptic ulcer in dialysis patients. 1
Response to 'Factors aside from
Helicobacter pylori play an important role in the occurrence of peptic ulcer in dialysis patients' We thank Dr Tseng et al. for their useful comments and references about the effects of Helicobacter pylori eradication therapy and the role of non-steroidal anti-inflammatory drugs (NSAIDs)/aspirin in dialysis patients. 1 H. pylori eradication therapy is well known to decrease peptic ulcer incidence and recurrence in long-term follow-up studies in both dialysis patients and patients with normal renal function. In our study, the prevalence of peptic ulcer in H. pylori-positive and -negative dialysis patients was 23.3 and 12.1%, respectively; most peptic ulcers in uninfected patients were healing to the red scar stage, and active ulcers were rare. 2 However, the recurrence rate of peptic ulcer was reported to be much higher in dialysis patients (25%) than in non-dialysis patients (3%) during two years' observation. 3 These data suggest that gastroduodenal mucosal injury in dialysis patients occurs frequently, irrespective of H. pylori infection.
NSAIDs/aspirin intake, systemic/local circulatory failure, hypergastrinemia, high ammonia levels, and enhanced inflammation were considered to be the causes of mucosal injury in H. pylori-negative dialysis patients. 2 Dialysis patients frequently receive NSAIDs/aspirin for preventing cardiovascular diseases, and NSAIDs/aspirin should play important roles for preventing the development of peptic ulcer. 4 In our unpublished data, most cases receiving NSAIDs/aspirin were able to prevent active ulcer development by acid inhibitory drugs (that is, proton pump inhibitor and/or histamine receptor antagonist). Overall, we recommend that both H. pylori-positive and -negative dialysis patients receive frequent endoscopic checkups and anti-acid drugs, especially those with a history of peptic ulcer, hemorrhage, and use of anticoagulants and NSAIDs/ aspirin.
